Q2 FY2026 · ended Jun 30, 2026 · Revenue $37.59M, +98.6% YoY · Filed Aug 13, 2026
Eton Pharmaceuticals, Inc. (ETON) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $37.6 million and net income of $11.6 million. Free cash flow was $7.2 million. As of Jun 30, 2026 it held $26.8 million in cash and investments and $20.4 million in total debt.
Revenue
$37.59M
+98.6% vs year-ago quarter
Net income
$11.58M
+547.9% vs year-ago quarter
Operating cash flow
$7.25M
-8.8% vs year-ago quarter
Free cash flow
$7.25M
-8.9% vs year-ago quarter
EPS
$0.35
+600.0% vs prior quarter
Dividend per share
None
Shares outstanding
28.58M
+6.6% vs year-ago quarter
Net cash
$6.45M
Q2 FY2026
Operating margin
15.4%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ETON (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Deer Park, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1710340
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $37.6M | $24.3M | $21.3M | $22.5M | $18.9M |
| Operating income | $12.8M | $2.4M | $2.5M | -$1.4M | -$1.5M |
| Net income | $11.6M | $1.6M | $1.5M | -$1.9M | -$2.6M |
| Diluted EPS | $0.35 | $0.05 | — | -$0.07 | — |
| Operating cash flow | $7.3M | $7.4M | -$11.6M | $12.0M | $8.0M |
| Free cash flow | $7.2M | $7.3M | -$11.6M | $11.7M | $8.0M |
| Total assets | $115.8M | $97.7M | $92.1M | $104.5M | $101.7M |
| Total liabilities | $69.2M | $67.1M | $66.0M | $81.4M | $77.7M |
| Stockholders' equity | $46.6M | $30.6M | $26.2M | $23.1M | $24.0M |
| Cash and investments | $26.8M | $19.7M | $25.9M | $37.1M | $25.4M |
| Total debt | $20.4M | $19.5M | $31.1M | $28.1M | $27.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 28, 2026 |
All 421 Eton Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.